Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04941027 · ClinicalTrials.gov registry record
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 1,046
- Enrollment target
NCT04941027: Completed study, sponsored by Stanford University.
NCT04941027 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 1,046 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04941027 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 1,046 participants
- Enrollment target
Study Summary
The main goal of this protocol is to develop a well-phenotyped genetic biobank to identify genetic variants associated with the heterogeneous clinical presentations of Neurofibromatosis Type 1 (NF1). This will allow for improve understanding of NF1 pathogenesis and more personalized disease management. The investigators will conduct a GWAS analysis to identify common genetic risk variants associated with the development of cutaneous neurofibromas.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2025-11-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04941027
The ClinicalTrials.gov registry entry for NCT04941027 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,046 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04941027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04941027 about?
NCT04941027 is a clinical study titled "Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1". The main goal of this protocol is to develop a well-phenotyped genetic biobank to identify genetic variants associated with the heterogeneous clinical presentations of Neurofibromatosis Type 1 (NF1). This will allow for improve understanding of NF1 pathogenesis and more personalized disease manageme...
What is the current status of trial NCT04941027?
This trial is currently completed. The enrollment target is 1,046 participants. The study started on 2021-05-07. Estimated completion is 2025-11-24.
Who is sponsoring clinical trial NCT04941027?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.